FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | Relenza | Tamiflu | H5N1

Relenza outperforms Tamiflu in bird flu study


The antiviral Relenza has won a battle over Tamiflu in the competition for government contracts from governments anxious about a possible bird flu epidemic. New research published in Nature demonstrates that Relenza is better than Tamiflu in guarding against H5N1. In the test, patients infected with the H5N1 virus demonstrated resistance to Tamiflu but were helped by Relenza, which is made by GlaxoSmithKline. And analysts saw the results as a sign that governments around the world could start buying large quantities of Relenza as one line of defense against a human pandemic.

"Antiviral medicines are a key component of any flu pandemic response plan and the Nature article further highlights the important role of zanamivir (Relenza) in preparing for a future pandemic," said GSK Pharmaceuticals Europe president Eddie Gray.

- read the article from The Age

ALSO: Indonesian officials still stubbornly refuse to turn over samples of new bird flu strains unless it is guaranteed access to any new vaccines that are developed from it. Report

Related Articles:
Tamiflu resistant to seasonal strains
GSK nabs EU approval for pandemic shot

More stories about Vaccine   Relenza   Tamiflu   H5N1  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.